BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel SY, Carbone J, Jolles S. The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. Front Immunol. 2019;10:33. [PMID: 30800120 DOI: 10.3389/fimmu.2019.00033] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 12.7] [Reference Citation Analysis]
Number Citing Articles
1 Jolles S, Michallet M, Agostini C, Albert MH, Edgar D, Ria R, Trentin L, Lévy V. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. Eur J Haematol 2021;106:439-49. [PMID: 33453130 DOI: 10.1111/ejh.13580] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Hanitsch LG. [Prophylactic and therapeutic management of increased susceptibility to infection in patients with immunodeficiency]. Internist (Berl) 2022. [PMID: 35412057 DOI: 10.1007/s00108-022-01326-8] [Reference Citation Analysis]
3 Nelke C, Spatola M, Schroeter CB, Wiendl H, Lünemann JD. Neonatal Fc Receptor-Targeted Therapies in Neurology. Neurotherapeutics 2022. [PMID: 34997443 DOI: 10.1007/s13311-021-01175-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Jolles S, Smith BD, Vinh DC, Mallick R, Espinoza G, DeKoven M, Divino V. Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies. Leuk Lymphoma 2021;:1-10. [PMID: 34702119 DOI: 10.1080/10428194.2021.1992761] [Reference Citation Analysis]
5 Cauchi M, Willis M, Andrews A, Backx M, Brownlee W, Ford HL, Gran B, Jolles S, Price S, Rashid W, Schmierer K, Tallantyre EC. Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline. Pract Neurol 2022:practneurol-2022-003370. [PMID: 35863879 DOI: 10.1136/practneurol-2022-003370] [Reference Citation Analysis]
6 Ohmoto A, Fuji S, Shultes KC, Savani BN, Einsele H. Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia. Bone Marrow Transplant 2022. [PMID: 35440805 DOI: 10.1038/s41409-022-01680-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Piza CFST, Aranda CS, Solé D, Jolles S, Condino-Neto A. Serum Protein Electrophoresis May Be Used as a Screening Tool for Antibody Deficiency in Children and Adolescents. Front Immunol 2021;12:712637. [PMID: 34497609 DOI: 10.3389/fimmu.2021.712637] [Reference Citation Analysis]
8 Šedivá A, Milota T, Litzman J, Quinti I, Meyts I, Burns S, Jolles S. Medical algorithm: Diagnosis and management of antibody immunodeficiencies. Allergy 2021;76:3841-4. [PMID: 34037990 DOI: 10.1111/all.14961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Gatti A, Buccisano F, Scupoli MT, Brando B. The ISCCA flow protocol for the monitoring of anti-CD20 therapies in autoimmune disorders. Cytometry B Clin Cytom 2021;100:194-205. [PMID: 32598578 DOI: 10.1002/cyto.b.21930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Monleón Bonet C, Waser N, Cheng K, Tzivelekis S, Edgar JDM, Sánchez-Ramón S. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants. Expert Rev Clin Immunol 2020;16:911-21. [PMID: 32783541 DOI: 10.1080/1744666X.2020.1807328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sogkas G, Dubrowinskaja N, Adriawan IR, Anim M, Witte T, Schmidt RE, Atschekzei F. High frequency of variants in genes associated with primary immunodeficiencies in patients with rheumatic diseases with secondary hypogammaglobulinaemia. Ann Rheum Dis 2020:annrheumdis-2020-218280. [PMID: 33046446 DOI: 10.1136/annrheumdis-2020-218280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mustafa SS, Jamshed S, Vadamalai K, Ramsey A. Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia. PLoS One 2021;16:e0258529. [PMID: 34653210 DOI: 10.1371/journal.pone.0258529] [Reference Citation Analysis]
13 Varnas D, Jankauskienė A. Pneumocystis Jirovecii Pneumonia in a Kidney Transplant Recipient 13 Months after Transplantation: A Case Report and Literature Review. Acta Med Litu 2021;28:136-44. [PMID: 34393636 DOI: 10.15388/Amed.2020.28.1.5] [Reference Citation Analysis]
14 Shields AM, Venkatachalam S, Shafeek S, Paneesha S, Ford M, Sheeran T, Kelly M, Qureshi I, Salhan B, Karim F, De Silva N, Stones J, Lee S, Khawaja J, Kaudlay PK, Whitmill R, Kakepoto GN, Parry HM, Moss P, Faustini SE, Richter AG, Drayson MT, Basu S. SARS-CoV-2 vaccine responses following CD20-depletion treatment in patients with haematological and rheumatological disease: a West Midlands Research Consortium study. Clin Exp Immunol 2022;207:3-10. [PMID: 35020852 DOI: 10.1093/cei/uxab018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Deyà-Martínez A, Gordón Y, Molina-Anguita C, Vlagea A, Piquer M, Juan M, Esteve-Solé A, Antón J, Madrid Á, García-García A, Plaza AM, Armangue T, Alsina L. Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease? Neurol Neuroimmunol Neuroinflamm 2020;7:e724. [PMID: 32376706 DOI: 10.1212/NXI.0000000000000724] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Ponsford MJ, Steven R, Bramhall K, Burgess M, Wijetilleka S, Carne E, McGuire F, Price CR, Moody M, Zouwail S, Tahir T, Farewell D, El-Shanawany T, Jolles SRA. Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID). J Clin Pathol 2020;73:587-92. [PMID: 32094276 DOI: 10.1136/jclinpath-2019-206235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
17 Borte M, Anderson-smits C, Hermann C. Update on real-world use of facilitated subcutaneous immunoglobulin and immune globulin subcutaneous (human) 20% solution in patients with immunodeficiencies: poster extracts from the 19th Biennial Meeting of the European Society for Immunodeficiencies. Expert Review of Clinical Immunology 2021;17:7-8. [DOI: 10.1080/1744666x.2021.1913122] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ponsford MJ, Pecoraro A, Jolles S. Clozapine-associated secondary antibody deficiency. Curr Opin Allergy Clin Immunol 2019;19:553-62. [PMID: 31567398 DOI: 10.1097/ACI.0000000000000592] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
19 Szczawinska-Poplonyk A, Schwartzmann E, Bukowska-Olech E, Biernat M, Gattner S, Korobacz T, Nowicki F, Wiczuk-Wiczewska M. The pediatric common variable immunodeficiency - from genetics to therapy: a review. Eur J Pediatr 2021. [PMID: 34939152 DOI: 10.1007/s00431-021-04287-6] [Reference Citation Analysis]
20 Rong Y, Hassan MM, Ouyang Q, Chen Q. Lanthanide ion (Ln3+ )-based upconversion sensor for quantification of food contaminants: A review. Compr Rev Food Sci Food Saf 2021;20:3531-78. [PMID: 34076359 DOI: 10.1111/1541-4337.12765] [Reference Citation Analysis]
21 Jablonka A, Etemadi H, Adriawan IR, Ernst D, Jacobs R, Buyny S, Witte T, Schmidt RE, Atschekzei F, Sogkas G. Peripheral Blood Lymphocyte Phenotype Differentiates Secondary Antibody Deficiency in Rheumatic Disease from Primary Antibody Deficiency. J Clin Med 2020;9:E1049. [PMID: 32272789 DOI: 10.3390/jcm9041049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Chapel H, Patel S. Defining B-cell defects and correlation with complications in patients with common variable immune deficiency. Journal of Allergy and Clinical Immunology 2019;144:654-5. [DOI: 10.1016/j.jaci.2019.06.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Houen G. Therapeutic Antibodies: An Overview. Methods Mol Biol 2022;2313:1-25. [PMID: 34478129 DOI: 10.1007/978-1-0716-1450-1_1] [Reference Citation Analysis]
24 Ponsford MJ, Shillitoe BMJ, Humphreys IR, Gennery AR, Jolles S. COVID-19 and X-linked agammaglobulinemia (XLA) - insights from a monogenic antibody deficiency. Curr Opin Allergy Clin Immunol 2021;21:525-34. [PMID: 34596095 DOI: 10.1097/ACI.0000000000000792] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Redenbaugh V, Flanagan EP. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD. Neurotherapeutics 2022. [PMID: 35267170 DOI: 10.1007/s13311-022-01206-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Ponsford MJ, Steven R, Bramhall K, Burgess M, Wijetilleka S, Carne E, McGuire F, Price CR, Moody M, Zouwail S, Tahir T, Farewell D, El-Shanawany T, Jolles SRA. Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID). J Clin Pathol 2020;73:587-92. [PMID: 32094276 DOI: 10.1136/jclinpath-2019-206235] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
27 Wijetilleka S, Jayne D, Mukhtyar C, Karim MY. Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases. Lupus Sci Med 2019;6:e000337. [PMID: 31413852 DOI: 10.1136/lupus-2019-000337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Maglione PJ, Ko HM, Tokuyama M, Gyimesi G, Soof C, Li M, Sanchez E, Chen H, Radigan L, Berenson J, Cunningham-Rundles C. Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies. J Allergy Clin Immunol Pract 2020;8:283-291.e1. [PMID: 31430592 DOI: 10.1016/j.jaip.2019.08.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
29 Link H, Kerkmann M, Holtmann L; for the Working Groups Supportive Care (AGSMO), Medical Oncology (AIO) of the German Cancer Society (DKG). Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections. Support Care Cancer. [DOI: 10.1007/s00520-022-06920-y] [Reference Citation Analysis]
30 Grammatikos A, Bright P, Bhatnagar R, Johnston S. How to investigate a suspected immune deficiency in adults. Respir Med 2020;171:106100. [PMID: 32799060 DOI: 10.1016/j.rmed.2020.106100] [Reference Citation Analysis]
31 Van Landingham CB, Keast DR, Longnecker MP. Serum Concentration of Antibodies to Mumps, but Not Measles, Rubella, or Varicella, Is Associated with Intake of Dietary Fiber in the NHANES, 1999-2004. Nutrients 2021;13:813. [PMID: 33801237 DOI: 10.3390/nu13030813] [Reference Citation Analysis]
32 Snyder K, Quddus R, Hollingsworth AD, Kirshenbaum K, Grier DG. Holographic immunoassays: direct detection of antibodies binding to colloidal spheres. Soft Matter 2020;16:10180-6. [PMID: 33057563 DOI: 10.1039/d0sm01351j] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Baumann U, Fasshauer M, Pausch C, Wittkowski H, Hermann C, Pittrow D, Borte M. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases. Immunotherapy 2021. [PMID: 34743590 DOI: 10.2217/imt-2021-0167] [Reference Citation Analysis]
34 Jahnz-RÓŻyk K, WiĘsik-Szewczyk E, RoliŃski J, Siedlar M, JĘdrzejczak W, Sydor W, Tomaszewska A. Secondary immunodeficiencies with predominant antibody deficiency: multidisciplinary perspectives of Polish experts. Cent Eur J Immunol 2020;45:334-41. [PMID: 33437186 DOI: 10.5114/ceji.2020.101265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Ballow M, Sánchez-ramón S, Walter JE. Secondary Immune Deficiency and Primary Immune Deficiency Crossovers: Hematological Malignancies and Autoimmune Diseases. Front Immunol 2022;13:928062. [DOI: 10.3389/fimmu.2022.928062] [Reference Citation Analysis]
36 Więsik-Szewczyk E, Jahnz-Różyk K. From infections to autoimmunity: Diagnostic challenges in common variable immunodeficiency. World J Clin Cases 2020; 8(18): 3942-3955 [PMID: 33024751 DOI: 10.12998/wjcc.v8.i18.3942] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Allegra A, Tonacci A, Musolino C, Pioggia G, Gangemi S. Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia. Front Immunol 2021;12:738915. [PMID: 34759921 DOI: 10.3389/fimmu.2021.738915] [Reference Citation Analysis]
38 Borte M, Raffac S, Hrubiško M, Jahnz-Rozyk K, Garcia E, McCoy B, Chavan S, Nagy A, Yel L. Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry study. Immunotherapy 2022. [PMID: 35443783 DOI: 10.2217/imt-2021-0336] [Reference Citation Analysis]
39 Ye C, Chen W, Gao Q, Chen Y, Song X, Zheng S, Liu J. Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China. Med Sci Monit 2021;27:e930241. [PMID: 34238914 DOI: 10.12659/MSM.930241] [Reference Citation Analysis]
40 Kobayashi RH, Litzman J, Rizvi S, Kreuwel H, Hoeller S, Gupta S. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases. Immunotherapy 2022. [PMID: 34986666 DOI: 10.2217/imt-2021-0313] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Peter HH, Ochs HD, Cunningham-Rundles C, Vinh DC, Kiessling P, Greve B, Jolles S. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. J Allergy Clin Immunol 2020;146:479-491.e5. [PMID: 32896308 DOI: 10.1016/j.jaci.2020.07.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
42 Karakulska-Prystupiuk E, Dwilewicz-Trojaczek J, Drozd-Sokołowska J, Kmin E, Chlebus M, Szczypińska K, Boguradzki P, Tomaszewska A, Mądry K, Biliński J, Basak GW, Jędrzejczak WW. Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation-a single-center analysis. Ann Hematol 2021;100:3007-16. [PMID: 34477951 DOI: 10.1007/s00277-021-04649-y] [Reference Citation Analysis]
43 Zaidi SZA, Zaidi FZ, AlShehry N, Zaidi ARZ, Zaidi SZ, Abdullah SM. Aging and therapy-related hypogammaglobulinemia causing pneumonia: An overlooked curable entity in the chaotic COVID-19 pandemic. J Med Virol 2021;93:202-3. [PMID: 32681654 DOI: 10.1002/jmv.26318] [Reference Citation Analysis]
44 Szepanowski F, Warnke C, Meyer Zu Hörste G, Mausberg AK, Hartung HP, Kleinschnitz C, Stettner M. Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. CNS Drugs 2021;35:1173-88. [PMID: 34657228 DOI: 10.1007/s40263-021-00863-4] [Reference Citation Analysis]
45 Shields AM, Patel SY. Infections in the immunocompromised host: primary immunodeficiency disorders. Medicine 2021;49:603-10. [DOI: 10.1016/j.mpmed.2021.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Tiotiu A, Salvator H, Jaussaud R, Jankowski R, Couderc LJ, Catherinot E, Devillier P. Efficacy of immunoglobulin replacement therapy and azithromycin in severe asthma with antibody deficiency. Allergol Int 2020;69:215-22. [PMID: 31812484 DOI: 10.1016/j.alit.2019.10.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
47 Derman BA, Schlei Z, Parsad S, Mullane K, Knoebel RW. Changes in Intravenous Immunoglobulin Usage for Hypogammaglobulinemia After Implementation of a Stewardship Program. JCO Oncol Pract 2021;17:e445-53. [PMID: 32822257 DOI: 10.1200/OP.20.00312] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Marcacci G, Fiorentino G, Volzone F, Falcone U, Parrella R, Donnarumma D, D'Ovidio S, Annunziata A, Micallo G, Portella G, De Chiara A, De Filippi R, Crisci S, Pinto A. Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab. Infect Agent Cancer 2021;16:38. [PMID: 34078415 DOI: 10.1186/s13027-021-00376-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
49 Scarpa R, Dell'Edera A, Felice C, Buso R, Muscianisi F, Finco Gambier R, Toffolo S, Grossi U, Giobbia M, Barberio G, Landini N, Facchini C, Agostini C, Rattazzi M, Cinetto F. Impact of Hypogammaglobulinemia on the Course of COVID-19 in a Non-Intensive Care Setting: A Single-Center Retrospective Cohort Study. Front Immunol 2022;13:842643. [PMID: 35359947 DOI: 10.3389/fimmu.2022.842643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Khan SR, Vanoverschelde A, Lahousse L, Peeters RP, van Hagen PM, Brusselle G, Chaker L, Dalm VASH. Serum Immunoglobulins, Pneumonia Risk, and Lung Function in Middle-Aged and Older Individuals: A Population-Based Cohort Study. Front Immunol 2022;13:868973. [PMID: 35757724 DOI: 10.3389/fimmu.2022.868973] [Reference Citation Analysis]
51 Mustafa SS, Jamshed S, Vadamalai K, Ramsey A. The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab. Clin Lymphoma Myeloma Leuk 2020;20:e590-6. [PMID: 32646834 DOI: 10.1016/j.clml.2020.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Sarmiento E, Jimenez M, di Natale M, Rodriguez-Ferrero M, Anaya F, Lopez-Hoyos M, Rodrigo E, Arias M, Perello M, Seron D, Karanovic B, Ezzahouri I, Mezzano S, Jaramillo M, Calahorra L, Alarcon A, Navarro J, Muñoz P, Carbone J. Secondary antibody deficiency is associated with development of infection in kidney transplantation: Results of a multicenter study. Transpl Infect Dis 2021;23:e13494. [PMID: 33064917 DOI: 10.1111/tid.13494] [Reference Citation Analysis]
53 Pavlakou P, Papasotiriou M, Ntrinias T, Kourakli A, Bratsiakou A, Goumenos DS, Papachristou E. Case Report: Kidney Transplantation in a Patient With Acquired Agammaglobulinemia and SLE. Issues and Challenges. Front Med (Lausanne) 2021;8:665475. [PMID: 33777986 DOI: 10.3389/fmed.2021.665475] [Reference Citation Analysis]
54 Melega S, Brogan P, Cleary G, Hersh AO, Kasapcopur O, Rangaraj S, Yeung RSM, Zeft A, Cooper J, Pordeli P, Kirchner P, Lehane PB. Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis. Rheumatol Ther. [DOI: 10.1007/s40744-022-00433-0] [Reference Citation Analysis]
55 Macy E. Immune-Related Adverse Drug Reactions and Immunologically Mediated Drug Hypersensitivity. Immunol Allergy Clin North Am 2020;40:635-47. [PMID: 33012325 DOI: 10.1016/j.iac.2020.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
56 Keith PK, Cowan J, Kanani A, Kim H, Lacuesta G, Lee JK, Chen J, Park M, Gladiator A. Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study. Allergy Asthma Clin Immunol 2022;18. [DOI: 10.1186/s13223-022-00709-8] [Reference Citation Analysis]
57 Mallick R, Divino V, Smith BD, Jolles S, DeKoven M, Vinh DC. Infections in secondary immunodeficiency patients treated with Privigen® or Hizentra®: a retrospective US administrative claims study in patients with hematological malignancies. Leuk Lymphoma 2021;:1-11. [PMID: 34569910 DOI: 10.1080/10428194.2021.1961233] [Reference Citation Analysis]
58 Grywalska E, Zaborek M, Łyczba J, Hrynkiewicz R, Bębnowska D, Becht R, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, Góźdź S, Roliński J, Niedźwiedzka-Rystwej P. Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review. Cells 2020;9:E2398. [PMID: 33147729 DOI: 10.3390/cells9112398] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]